Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”

SIMPLE SUMMARY: Multiple myeloma (MM) is characterized by the presence of deregulated bone metabolism. Restoring bone turnover is essential for patients with MM. We prospectively evaluated the impact of the anti-CD38 monoclonal antibody daratumumab on markers of bone remodeling among patients with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Hatjiharissi, Evdoxia, Katodritou, Eirini, Eleutherakis-Papaiakovou, Evangelos, Verrou, Evgenia, Gavriatopoulou, Maria, Leonidakis, Alexandros, Manousou, Kyriaki, Delimpasi, Sosana, Malandrakis, Panagiotis, Kyrtsonis, Marie-Christine, Papaioannou, Maria, Symeonidis, Argiris, Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179322/
https://www.ncbi.nlm.nih.gov/pubmed/35681747
http://dx.doi.org/10.3390/cancers14112768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179322/
https://www.ncbi.nlm.nih.gov/pubmed/35681747
http://dx.doi.org/10.3390/cancers14112768

Ejemplares similares